Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Emily M. J., Aponte-Collazo, Lucas J., Pathmasiri, Wimal, Rushing, Blake R., Barker, Natalie K., Partridge, Megan C., Li, Yuan-Yuan, White, Cody A., Greer, Yoshimi E., Herring, Laura E., Lipkowitz, Stanley, Sumner, Susan C. J., Iwanowicz, Edwin J., Graves, Lee M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103842/
https://www.ncbi.nlm.nih.gov/pubmed/37063293
http://dx.doi.org/10.3389/fphar.2023.1136317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103842/
https://www.ncbi.nlm.nih.gov/pubmed/37063293
http://dx.doi.org/10.3389/fphar.2023.1136317

Ejemplares similares